The European Conference on Infections in Leukaemia (ECIL) brings together experts in several fields to produce evidence-based recommendations from comprehensive literature reviews.  The 10th ECIL meeting in 2024 addressed new developments in CMV management after allogeneic HCT, and recommendations are presented in this Review. Management recommendations include diagnostics, such as immune monitoring, antiviral prophylaxis with letermovir, management of resistant and refractory CMV infections, and paediatric aspects of CMV management.

Our medical experts have developed this in-depth overview of maribavir as a treatment option for refractory cytomegalovirus (CMV) infections in adult patients following hematopoietic stem cell transplantation (HSCT). 

Join Prof. Dr. Johan Maertens as he shares key insights and takeaways from the EBMT Congress 2024, held in Glasgow, UK. His discussion centers on infectious complications following CAR-T therapy and stem cell transplantation, with a particular focus on the management of cytomegalovirus infections. The congress also showcased updates on innovative  CMV treatment options and advanced management strategies presented during various sessions.

Discover new innovative strategies for managing challenging CMV infections post-HSCT presented by Prof. Dr. Johan Maertens. This comprehensive presentation delves into the latest advancements in antiviral therapies and the impact of CMV resistance on patient outcomes, using a practical patient case of 59-year-old man with acute leukemia who experienced multiple CMV reactivations post-transplantation, requiring multiple lines of antiviral treatment.  

Prof. Ann De Becker, hematologist at UZ Brussel, is sharing her experience with Livtencity 1 year after launch. 

Join us for the latest advancements, therapeutic strategies and insights in CMV management post-transplantation.

Prof. Dr. Johan Maertens shared an in-depth case study of a 59-year-old patient with acute leukemia who underwent haplo-identical stem cell transplantation. The patient faced a series of complex complications, including challenging CMV reactivations, renal impairment, myelotoxicity, and intercurrent bacteremias. A pivotal moment in the patient’s treatment journey came with their enrolment in the Solstice Trial¹, a phase 3 randomized controlled study comparing maribavir to investigator-assigned therapies. 

Solstice trial

Dénomination du médicament : LIVTENCITY 200 mg comprimés pelliculés
Principe actif: maribavir
Indications thérapeutiques :
LIVTENCITY est indiqué dans le traitement de l’infection et/ou de la maladie à cytomégalovirus (CMV) réfractaire (avec ou sans résistance) à un ou plusieurs traitements antérieurs, y compris le ganciclovir, le valganciclovir, le cidofovir ou le foscarnet chez les patients adultes ayant reçu une greffe de cellules souches hématopoïétiques (GCSH) ou une greffe d’organe solide (GOS).
Classe pharmacothérapeutique : Antiviraux à usage systémique, antiviraux à action directe, Code ATC : J05AX10. 

Mechanism of action of livtencity

Who can benefit from livtencity reimbursement?

La spécialité pharmaceutique à base de maribavir fait l’objet d’un remboursement* pour le traitement des bénéficiaires, de tout épisode de CMV infection et/ou CMV maladie pour2 :

• les patients adultes après une transplantation allogénique de cellules souches hématopöiétiques ou après une transplantation d’organe solide.

• le traitement :